Applied Genetic Technologies Corp AGTC:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
3.95 -0.05   -1.25%--65,751112.6K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 1/17/2018

Latest News Headlines for Applied Genetic Technologies Corp

No News for Applied Genetic Technologies Corp

Peers Information HelpAGTC Applied Genetic Technologies Corp vs. Peers

AGTC
Applied Genetic Technologies Corp
9.72%
Vernalis plc (ADR)
0.00%
CTI BioPharma Corp
27.24%
-16.88%
Cerecor Inc
DURECT Corporation
25.84%
AGTC
Applied Genetic Technologies Corp
0.00%
Vernalis plc (ADR)
0.00%
CTI BioPharma Corp
0.00%
Cerecor Inc
0.00%
DURECT Corporation
0.00%
-1.25%
AGTC
Applied Genetic Technologies Corp
Vernalis plc (ADR)
0.00%
-2.29%
CTI BioPharma Corp
Cerecor Inc
2.31%
0.00%
DURECT Corporation
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings
10-K

This report contains detailed information about the company's business finances and management.

10-Q

Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).

http://www.agtc.com/

Loading...

collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open4.10
Previous Close3.95
Day High4.1431
Day Low3.95
52 Week High1/20/2017 | 9.45
52 Week Low11/7/2017 | 3.25
% Off 52 Week High-58.20%
% Off 52 Week Low21.54%
Beta (5 Yr)1.6
Volatility Avg1/17/2018 | 56.53
10-Day Avg. Volume112,619
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | -0.26
P/E Ratio9/30/2017 | --
Market CapMicro Cap | 71.47M
Shares Outstanding18.09M
Float15.1M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Ex-Date--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

expand, down-facing arrow indicating expanded view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short230.88K
Short Ratio2.7
Short % of Float1.53%
As of 12/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.